Related references
Note: Only part of the references are listed.Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening
Jeffrey W. Tyner et al.
CANCER RESEARCH (2013)
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients
Mengmeng Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping
Christina Laufer et al.
NATURE METHODS (2013)
Novel Computational Approaches to Polypharmacology as a Means to Define Responses to Individual Drugs
Lei Xie et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors
Lifang Xie et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Exploring drug combinations in genetic interaction network
Yin-Ying Wang et al.
BMC BIOINFORMATICS (2012)
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
S. V. Holt et al.
BRITISH JOURNAL OF CANCER (2012)
Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network
Galina Lebedeva et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani et al.
NATURE BIOTECHNOLOGY (2012)
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Feng Zhu et al.
NUCLEIC ACIDS RESEARCH (2012)
PubChem's BioAssay Database
Yanli Wang et al.
NUCLEIC ACIDS RESEARCH (2012)
ChEMBL: a large-scale bioactivity database for drug discovery
Anna Gaulton et al.
NUCLEIC ACIDS RESEARCH (2012)
Genetic Interactions in Cancer Progression and Treatment
Alan Ashworth et al.
CELL (2011)
Principles and Strategies for Developing Network Models in Cancer
Dana Pe'er et al.
CELL (2011)
Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
Sen Zhang et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Searching for synthetic lethality in cancer
Rachel Brough et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2011)
Predicting selective drug targets in cancer through metabolic networks
Ori Folger et al.
MOLECULAR SYSTEMS BIOLOGY (2011)
Systematic exploration of synergistic drug pairs
Murat Cokol et al.
MOLECULAR SYSTEMS BIOLOGY (2011)
Interrogating the kinome
Chao Zhang et al.
NATURE BIOTECHNOLOGY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
A mammalian functional-genetic approach to characterizing cancer therapeutics
Hai Jiang et al.
NATURE CHEMICAL BIOLOGY (2011)
High drug attrition rates-where are we going wrong?
Lisa Hutchinson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
The productivity crisis in pharmaceutical R&D
Fabio Pammolli et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
PROMISCUOUS: a database for network-based drug-repositioning
Joachim von Eichborn et al.
NUCLEIC ACIDS RESEARCH (2011)
RNAi-Based Screening Identifies Kinases Interfering with Dioxin-Mediated Up-Regulation of CYP1A1 Activity
David Gilot et al.
PLOS ONE (2011)
Modulatory profiling identifies mechanisms of small molecule-induced cell death
Adam J. Wolpaw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Dynamical and Structural Analysis of a T Cell Survival Network Identifies Novel Candidate Therapeutic Targets for Large Granular Lymphocyte Leukemia
Assieh Saadatpour et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data
Xing-Ming Zhao et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis
Sergio Iadevaia et al.
CANCER RESEARCH (2010)
A side effect resource to capture phenotypic effects of drugs
Michael Kuhn et al.
MOLECULAR SYSTEMS BIOLOGY (2010)
Quantitative analysis of fitness and genetic interactions in yeast on a genome scale
Anastasia Baryshnikova et al.
NATURE METHODS (2010)
Advances in understanding cancer genomes through second-generation sequencing
Matthew Meyerson et al.
NATURE REVIEWS GENETICS (2010)
Targeting the cancer kinome through polypharmacology
Zachary A. Knight et al.
NATURE REVIEWS CANCER (2010)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
Detecting drug targets with minimum side effects in metabolic networks
Z. Li et al.
IET SYSTEMS BIOLOGY (2009)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie et al.
NATURE (2009)
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Joseph Lehar et al.
NATURE BIOTECHNOLOGY (2009)
RNAi screening: tips and techniques
Sonia Sharma et al.
NATURE IMMUNOLOGY (2009)
Statistical methods for analysis of high-throughput RNA interference screens
Amanda Birmingham et al.
NATURE METHODS (2009)
Mechanisms of drug combinations: interaction and network perspectives
Jia Jia et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Synthetic Lethality -- A New Direction in Cancer-Drug Development.
J. Dirk Iglehart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Finding multiple target optimal intervention in disease-related molecular network
Kun Yang et al.
MOLECULAR SYSTEMS BIOLOGY (2008)
Models from experiments: combinatorial drug perturbations of cancer cells
Sven Nelander et al.
MOLECULAR SYSTEMS BIOLOGY (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Network pharmacology: the next paradigm in drug discovery
Andrew L. Hopkins
NATURE CHEMICAL BIOLOGY (2008)
Expression of a chimeric CSF1R-LTK mediates ligand-dependent neurite outgrowth
Shigeru Yamada et al.
NEUROREPORT (2008)
Defining genetic interaction
Ramamurthy Mani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Angelique W. Whitehurst et al.
NATURE (2007)
Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf
M. Marzec et al.
ONCOGENE (2007)
Prediction of drug combination chemosensitivity in human bladder cancer
Dmytro M. Havaleshko et al.
MOLECULAR CANCER THERAPEUTICS (2007)
AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer
T. Furukawa et al.
ONCOGENE (2006)
Strategies for optimizing combinations of molecularly targeted anticancer agents
Janet E. Dancey et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Functional classification of drugs by properties of their pairwise interactions
P Yeh et al.
NATURE GENETICS (2006)
Analysis of cell-based RNAi screens
Michael Boutros et al.
GENOME BIOLOGY (2006)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression
A Dey et al.
MOLECULAR BIOLOGY OF THE CELL (2000)
Share Paper
